Laquinimod Catalog No.:M11360-2 Smiles: OC(=O)C1CCN(CC1)C1=NC=C(C=C1Cl)C(=O)NC1=NC(=C(S1)N1CCN(CC1)C1CCCCC1)C1=CC(Cl)=CS1

Smiles: OC(=O)C1CCN(CC1)C1=NC=C(C=C1Cl)C(=O)NC1=NC(=C(S1)N1CCN(CC1)C1CCCCC1)C1=CC(Cl)=CS1

Cidofovir is an acyclic nucleoside phosphonate

108(14):5620-5

2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide

CCC1=CC=C(CC2=CC=C3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=C2)C=C1

Laquinimod Catalog No.:M11360-2 Smiles: OC(=O)C1CCN(CC1)C1=NC=C(C=C1Cl)C(=O)NC1=NC(=C(S1)N1CCN(CC1)C1CCCCC1)C1=CC(Cl)=CS1Laquinimod, also known as, is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce